Results 221 to 230 of about 21,074 (263)

The physiology of incretins

Orvosi Hetilap, 2011
The discovery of incretins − glucagon-like peptide (GLP)-1 and glucose-dependent insulinotrop peptide (GIP) −, clarification of their physiological properties as well as therapeutic application of incretin-based blood glucose lowering drugs opened new perspectives in the medical management of type 2 diabetes.
openaire   +2 more sources

Incretin Pharmacology: A Review of the Incretin Effect and Current Incretin-Based Therapies

Cardiovascular & Hematological Agents in Medicinal Chemistry, 2012
Given the demonstrated importance of the incretin effect on the prandial insulin response, augmentation of the incretin effect in people with type 2 diabetes is an important pharmacological approach to glycemic management. In recent years, the use of incretin-based therapies, such as GLP-1 receptor agonists and DPP-4 inhibitors, has increased ...
openaire   +2 more sources

GLUCOREGULATORY ACTIONS OF INCRETINS/ANTI-INCRETINS

2023
Diabetes mellitus (DM) is a chronic debilitating and non-communicable disease characterized by chronic hyperglycemia and resulting from a defect in insulin secretion, insulin action, or both. Apart from these, defective actions of the gastrointestinal (GI) incretin hormones: glucagon-like peptide–1 (GLP-1) and glucose-dependent insulinotropic ...
openaire   +1 more source

Incretins and risk of neoplasia

BMJ, 2013
An association exists but causality has not yet been proved Incretin based treatment for type 2 diabetes improves hyperglycaemia without causing weight gain and is increasingly being used worldwide. Concerns have been raised about long term safety, as reported by Cohen,1 especially the risk of pancreatitis and pancreatic cancers—both adenocarcinoma ...
Thorvardur R, Halfdanarson, Rahul, Pannala   +1 more
openaire   +2 more sources

Pleiotropic effects of incretins and antidiabetics with incretine mechanism

Orvosi Hetilap, 2013
Discovery of physiological and pharmacological characteristics of incretins (glucagon-like peptide-1 and glucose-dependent insulinotrop polypeptide), and the introduction of various products of those into the clinical practice has fundamentally changed blood glucose lowering therapy in type 2 diabetes.
openaire   +2 more sources

Incretins and Lipid Metabolism

Current Medicinal Chemistry, 2018
Background: Recent findings indicate that incretin hormones and incretin-based therapies may affect the metabolism of lipoproteins, although the corresponding mechanisms are not clearly defined. Objective: To summarize the available data on the mechanisms linking incretins with the characteristics of serum lipoproteins and discuss the clinical ...
Vasilis, Tsimihodimos, Moses, Elisaf
openaire   +2 more sources

[Incretin and incretin-based therapies].

Nihon rinsho. Japanese journal of clinical medicine, 2010
GIP and GLP-1 are major incretins and secreted from K-cell and L-cell in response to meal ingestion, respectively. GIP and GLP-1 potentiate glucose-induced insulin secretion by binding GIP receptor and GLP-1 receptor, respectively, on pancreatic beta-cell and increasing intracellular cAMP concentration (incretin effect). GIP receptor and GLP-1 receptor
Norio, Harada, Nobuya, Inagaki
openaire   +1 more source

Cardiovascular benefits of incretins

BMJ, 2013
Cohen and colleagues make no mention of the evidence that treatment of type 2 diabetes with increasingly larger doses of sulfonylureas and insulin is not without serious risk from hypoglycaemia, weight gain, and possibly increased cardiovascular risk.1 A balanced account of this is needed in any review of incretins.
Anthony H, Barnett, Paul, O'Hare
openaire   +2 more sources

Incretins in obesity and diabetes

Annals of the New York Academy of Sciences, 2019
AbstractIncretins are hormones secreted from enteroendocrine cells after nutrient intake that stimulate insulin secretion from β cells in a glucose‐dependent manner. Glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) are the only two known incretins.
Chee W. Chia, Josephine M. Egan
openaire   +2 more sources

[Incretins].

Vnitrni lekarstvi, 2007
Insulin secretion is greater after peroral challenge than after intravenous glucose administration due to so-called incretin effect. The major incretins are glucagon-like peptide 1 and glucose-dependent-insulinotropic peptide. Physiology, pathophysiology and therapeutic implications of incretins in diabetes, neurodegenerative disorders and stress ...
J, Vrbíková, K, Vondra
openaire   +1 more source